Johnson & Johnson vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the world of pharmaceuticals, the Selling, General, and Administrative (SG&A) expenses are a crucial indicator of a company's operational efficiency. Over the past decade, Johnson & Johnson and Agios Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses.

From 2014 to 2023, Johnson & Johnson's SG&A expenses have remained relatively stable, averaging around $21 billion annually. This consistency reflects the company's robust operational strategies and market dominance. In contrast, Agios Pharmaceuticals, Inc. has experienced a significant increase in SG&A expenses, growing by over 500% from 2014 to 2020. This surge highlights Agios's aggressive expansion and investment in marketing and administrative capabilities.

While Johnson & Johnson's expenses peaked in 2018, Agios saw its highest SG&A expenses in 2020, indicating different strategic priorities. These trends offer valuable insights into how these companies navigate the competitive pharmaceutical landscape.